PTL-202 is Pacific Therapeutics’ latest formulation aimed at treating idiopathic pulmonary fibrosis (IPF) and liver cirrhosis. The company focuses on finding therapeutic solutions and reformulation of existing drugs to reduce side effects, aid in clinical testing of drugs with known toxicity and safety profiles, and reduce costs of research by avoiding unknown risks.
History of PTL-202
PTL 202 is a mixture of FDA approved pentoxifylline for treating leg cramps, and N-acetyl-cysteine (NAC) an amino acid and an extremely potent and important antioxidant. The drug was tested in preclinical mouse models successfully. It did not show any side-effects. The phase I clinical trials followed showing safety and tolerability profiles in healthy human hosts. Decrease in vasodilation was a positive effect. Increase in the therapeutic effects of PTL-202 was consistent and proportional to the increase in the amount of active ingredient in blood. The only side effects worth mentioning were dizziness and nausea associated with high levels of the drug in the blood.
Next Steps for PTL-202
Currently, the company’s strategy involves finalizing a fixed dosage for the drug to assure the correct ratio of active ingredients. So far, the proprietary dosage of once a day is safe and well tolerated by clinical trial volunteers. Fine tuning will then pave the way for regulatory filing, prescription of a precise dosage, proof of clinical trial data and commercialization of the drug.
Note: Pulmonary Fibrosis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.